Managed care's rebound looks real, but the easy bull case is early
Health insurers are finally showing signs that the medical-cost spike is easing, but that is not the same thing as a clean, durable margin reset across the group. The better trade still looks selective: some operators are stabilizing, while others remain too expensive or too exposed to unresolved Medicare Advantage and Medicaid pressure.
The rebound in managed care is real enough to respect, but too uneven to treat as an all-clear. The market is trying to turn one better quarter into a sector-wide margin recovery story, and that leap still looks premature. Reuters' May 13 reporting captured the tension well: costs are stabilizing, earnings beats are back, yet analysts still want another quarter before declaring a durable turn. We think that caution is right, because the latest results argue for selective recovery, not a clean reset for every major insurer.
The strongest evidence that the worst may be passing came from UNH
, and it was meaningful. UnitedHealth posted an 83.9% medical cost ratio in Q1, down 90 basis points year over year, and raised full-year adjusted EPS guidance to more than $18.25 from more than $17.75. That is not cosmetic improvement; it is what early-cycle stabilization looks like. But even there, management was still watching April and May utilization closely. That is the key distinction the easy bull case glosses over: if the recovery were fully established, management teams would be talking about normalization, not still checking whether the trend holds month to month.
The problem is that the group is not moving in lockstep. ELV raised guidance too, but its first quarter still showed an 86.8% benefit expense ratio, up 40 basis points, with elevated Medicaid cost trend offsetting better Medicare performance. HUM may be the clearest warning against declaring victory too early: it beat quarterly expectations and said medical and pharmacy trends were slightly better than expected, yet it kept full-year adjusted profit guidance unchanged. That muted response matters more than the beat itself. When one of the industry's most Medicare-exposed names refuses to translate a cleaner quarter into a higher full-year view, investors should read that as management telling you the visibility still is not good enough.
The market's own pricing says this is not a uniform recovery story.
That spread is too wide to support the idea that managed care has simply turned the corner as a group. HUM trading at 32.90x earnings with just 0.8% net margin and negative 1.4% EPS growth is a much harder underwriting case than ELV at 16.72x with a 2.6% net margin, even if both are participating in the rebound narrative. CI is the opposite case: a 2.52x P/E alongside 82.0% EPS growth suggests the market still sees company-specific complexity or skepticism, not a broad rerating. If this were a clean sector recovery, valuation dispersion would be narrowing faster than this.
Yes, bulls have a fair point: this was the best quarter for the group since the post-COVID period when utilization was unusually favorable, and some analysts now argue pricing is finally catching up to medical trend. CNC is the best exhibit for that case, with the stock up 41.6% year to date after a beat-and-raise quarter that investors took as proof cost discipline is working. But that argument still skips over the earnings hole the sector is climbing out of. Research cited in recent coverage says managed care companies are still underearning target margins by 34% to 400%, with especially large gaps at names like Humana and Centene. A rebound from depressed profitability is not the same thing as restored earnings power.
That is why we think the right framework is rebasing, not recovery. Public filings and recent earnings releases show revenue growth is still solid across the group — 11.8% at UNH, 12.6% at ELV, 10.1% at HUM, and 19.4% at CNC — but revenue was never the core problem. The issue was whether pricing, utilization, Stars exposure, and government-program mix could produce durable margins again. On that score, the evidence is mixed. UNH looks like the cleanest operator right now. ELV looks improved but still exposed to Medicaid noise. HUM still has to prove one better quarter can become a full-year earnings reset. CNC has momentum, but its negative 3.3% net margin and deeply negative EPS growth show how far the comeback still has to run.
The historical analogy here is not a classic cyclical snapback; it is the long normalization after COVID distorted utilization in both directions. Insurers first benefited when deferred care collapsed, then spent the next stretch absorbing catch-up utilization and government-plan pressure. That kind of unwind does not end neatly. It can produce exactly what the market is seeing now: one or two cleaner quarters, a burst of optimism, and then a slower grind as the remaining weak spots become impossible to ignore. That is why a selective stance is more credible than a blanket bullish call on managed care.
The takeaway is straightforward: managed care is no longer a pure damage-control story, but it is not a healed margin story either. The sector has earned a better tone, not a free pass. We would rather back the names showing real operating traction and reasonable valuation than chase the idea that every insurer is now on the same recovery path.
What would change our mind? Another quarter in which lower medical-cost pressure holds across both Medicare and Medicaid, and in which the laggards start raising full-year guidance instead of merely beating a quarter. Until then, the cleanest call is that the rebound is real, but the easy bull case is still early.
Our take, not advice. This is opinion commentary — informational only, not personalized investment recommendations. Markets carry risk. Do your own research and consider your own situation before any trade.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
